IDEXX Laboratories (IDXX) 10-Q 30 Jul 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 20, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Entity Registrant Name	IDEXX LABORATORIES INC /DE
Entity Central Index Key	874,716
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		92,005,024

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 163,152	$ 322,536
Marketable securities	180,870
Accounts receivable, net of reserves of $5,404 in 2015 and $4,306 in 2014	199,444	152,380
Inventories	184,500	160,342
Deferred income tax assets	37,509	37,689
Other current assets, net	67,559	86,451
Total current assets	833,034	759,398
Long-Term Assets:
Property and equipment, net	326,041	303,587
Goodwill	179,705	184,450
Intangible assets, net	57,517	65,122
Other long-term assets, net	81,073	71,654
Total long-term assets	644,336	624,813
TOTAL ASSETS	1,477,370	1,384,211
Current Liabilities:
Accounts payable	58,212	44,743
Accrued liabilities	190,441	195,351
Line of credit	498,000	549,000
Current portion of deferred revenue	28,775	31,812
Total current liabilities	775,428	820,906
Long-Term Liabilities:
Deferred income tax liabilities	39,261	41,688
Long-term debt	598,925	350,000
Long-term deferred revenue, net of current portion	23,871	21,665
Other long-term liabilities	31,334	32,363
Total long-term liabilities	693,391	445,716
Total liabilities	$ 1,468,819	$ 1,266,622
Commitments and Contingencies (Note 14)
Stockholders' Equity:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 102,347 and 101,947 shares in 2015 and 2014, respectively; Outstanding: 92,636 and 47,373 shares in 2015 and 2014, respectively	$ 10,235	$ 10,195
Additional paid-in capital	921,678	888,293
Deferred stock units: Outstanding: 240 and 235 units in 2015 and 2014, respectively	5,376	5,066
Retained earnings	231,070	1,675,299
Accumulated other comprehensive loss	(22,275)	(8,071)
Treasury stock, at cost: 9,711 and 54,574 shares in 2015 and 2014, respectively	(1,137,616)	(2,453,266)
Total IDEXX Laboratories, Inc. stockholders' equity	8,468	117,516
Noncontrolling interest	83	73
Total stockholders' equity	8,551	117,589
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 1,477,370	$ 1,384,211

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Condensed Consolidated Balance Sheets [Abstract]
Accounts receivable, reserves	$ 5,404	$ 4,306
Common stock, par value	$ 0.10	$ 0.10
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	102,347,000	101,947,000
Common Stock, shares outstanding	92,636,000	47,373,000
Deferred stock units, outstanding	240,000	235,000
Treasury stock, shares	9,711,000	54,574,000

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue:
Product revenue	$ 251,210	$ 237,515	$ 483,313	$ 456,907
Service revenue	162,133	152,607	312,507	293,418
Total revenue	413,343	390,122	795,820	750,325
Cost of Revenue:
Cost of product revenue	91,203	86,956	174,573	164,998
Cost of service revenue	89,383	84,648	172,946	164,712
Total cost of revenue	180,586	171,604	347,519	329,710
Gross profit	232,757	218,518	448,301	420,615
Expenses:
Sales and marketing	75,217	68,020	150,353	135,868
General and administrative	44,920	41,846	87,519	82,935
Research and development	24,317	25,433	49,323	48,547
Income from operations	88,303	83,219	161,106	153,265
Interest expense	(7,259)	(2,965)	(13,563)	(5,739)
Interest income	559	488	984	959
Income before provision for income taxes	81,603	80,742	148,527	148,485
Provision for income taxes	24,665	23,498	45,011	44,648
Net income	56,938	57,244	103,516	103,837
Less: Net income attributable to noncontrolling interest	26	26	10	34
Net income attributable to IDEXX Laboratories, Inc. stockholders	$ 56,912	$ 57,218	$ 103,506	$ 103,803
Earnings per Share:
Basic	$ 0.61	$ 0.56	$ 1.10	$ 1.01
Diluted	$ 0.60	$ 0.55	$ 1.09	$ 1
Weighted Average Shares Outstanding:
Basic	93,384	102,250	93,829	102,739
Diluted	94,306	103,590	94,934	104,160

Condensed Consolidated Stateme5

Condensed Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Condensed Consolidated Statements Of Comprehensive Income [Abstract]
Net income	$ 56,938	$ 57,244	$ 103,516	$ 103,837
Other comprehensive income, net of tax:
Foreign currency translation adjustments	7,298	2,200	(12,934)	3,479
Unrealized gain on net investment hedge	737		737
Unrealized (loss) gain on investments, net of tax expense of $12 and $31 in 2015 and $36 and $4 in 2014	(26)	59	7	5
Unrealized gain (loss) on derivative instruments:
Unrealized (loss) gain, net of tax (benefit) expense of ($1,233) and $1,849 in 2015 and ($890) and ($1,013) in 2014	(2,885)	(1,924)	4,300	(2,177)
Less: reclassification adjustment for losses (gains) included in net income, net of tax benefit (expense) of ($1,451) and ($2,704) in 2015 and $138 and $91 in 2014	(3,350)	251	(6,314)	102
Unrealized loss on derivative instruments	(6,235)	(1,673)	(2,014)	(2,075)
Other comprehensive gain (loss), net of tax	1,774	586	(14,204)	1,409
Comprehensive income	58,712	57,830	89,312	105,246
Less: comprehensive income attributable to noncontrolling interest	26	26	10	34
Comprehensive income attributable to IDEXX Laboratories, Inc.	$ 58,686	$ 57,804	$ 89,302	$ 105,212

Condensed Consolidated Stateme6

Condensed Consolidated Statements Of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Condensed Consolidated Statements Of Comprehensive Income [Abstract]
Unrealized gain on investments, tax expense (benefit)	$ 12	$ 36	$ 31	$ 4
Unrealized (loss) gain, tax (benefit) expense	(1,233)	(890)	1,849	(1,013)
Reclassification adjustment for losses (gains) included in net income, tax benefit (expense)	$ (1,451)	$ 138	$ (2,704)	$ 91

Condensed Consolidated Stateme7

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash Flows from Operating Activities:
Net income	$ 103,516	$ 103,837
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	32,944	28,089
Provision for uncollectible accounts	1,448	788
Benefit of deferred income taxes	(2,055)	(5,225)
Share-based compensation expense	9,642	8,820
Other	417	110
Tax benefit from share-based compensation arrangements	(8,746)	(7,960)
Changes in assets and liabilities:
Accounts receivable	(57,126)	(9,786)
Inventories	(16,023)	(5,575)
Other assets	32,792	(2,950)
Accounts payable	(2,992)	337
Accrued liabilities	(27,589)	(3,344)
Deferred revenue	(706)	8,139
Net cash provided by operating activities	65,522	115,280
Cash Flows from Investing Activities:
Purchases of property and equipment	(46,873)	(25,410)
Purchase of marketable securities	(190,370)
Proceeds from the sale and maturities of marketable securities	10,039
Proceeds from sale of equity investment		5,400
Acquisitions of a businesses, net of cash acquired	(383)	(1,161)
Acquisition of intangible asset		(175)
Net cash used by investing activities	(227,587)	(21,346)
Cash Flows from Financing Activities:
(Repayments) borrowings on revolving credit facilities, net	(51,000)	107,000
Debt issue costs	(127)	(1,156)
Issuance of long term debt	250,097
Payment of notes payable		(1,394)
Repurchases of common stock	(220,097)	(196,626)
Proceeds from exercises of stock options and employee stock purchase plans	15,650	14,707
Tax benefit from share-based compensation arrangements	8,746	7,960
Net cash provided (used) by financing activities	3,269	(69,509)
Net effect of changes in exchange rates on cash	(588)	1,565
Net (decrease) increase in cash and cash equivalents	(159,384)	25,990
Cash and cash equivalents at beginning of period	322,536	279,058
Cash and cash equivalents at end of period	$ 163,152	$ 305,048

Basis Of Presentation And Princ

Basis Of Presentation And Principles Of Consolidation	6 Months Ended
	Jun. 30, 2015
Basis Of Presentation And Principles Of Consolidation [Abstract]
Basis Of Presentation And Principles Of Consolidation	NOTE 1. BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION The accompanying condensed consolidated financial statements of IDEXX Laboratories, Inc. and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the requirements of Regulation S-X, Rule 10-01 for financial statements required to be filed as a part of this Quarterly Report on Form 10-Q. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to "IDEXX," the "Company," "we," "our" or "us" refer to IDEXX Laboratories, Inc. and its subsidiaries. The accompanying condensed consolidated financial statements include the accounts of IDEXX Laboratories, Inc. and our wholly-owned and majority-owned subsidiaries. We do not have any variable interest entities for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation. The accompanying condensed consolidated financial statements reflect, in the opinion of our management, all adjustments necessary for a fair statement of our financial position and results of operations. All such adjustments are of a recurring nature. The consolidated balance sheet data at December 31, 2014 was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three and six months ended June 30 , 2015 are not necessarily indicative of the results to be expected for the full year or any future period. These condensed consolidated financial statements should be read in conjunction with this Quarterly Report on Form 10- Q for the quarter ended June 30 , 2015 and our Annual Report on Form 10-K for the year ended December 31, 2014 (the “2014 Annual Report”) filed with the U.S. Securities and Exchange Commission (“SEC”). Stock Split On May 6, 2015, we announced a two-for-one split of our outstanding shares of common stock which was effected through a stock dividend that was paid through the issuance of treasury shares. The stock split entitled each stockholder of record at the close of business on May 18, 2015 to receive one additional share of common stock for each outstanding share of common stock held. The additional shares of our common stock paid pursuant to the stock split were distributed by the Company’s transfer agent on June 15, 2015. All share and per share amounts in the condensed consolidated balance sheets, condensed consolidated statement of operations and notes to the condensed consolidated financial statements retroactively reflect the effect of the stock split unless otherwise noted. Reclassifications Certain prior year amounts have been reclassified to conform with the current year presentation. Such reclassifications had no material impact on previously reported results of operations, financial position or cash flows.

Accounting Policies

Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Accounting Policies	Note 2. ACCOUNTING POLICIES The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and six months ended June 30 , 2015 are consistent with those discussed in Note 2 to the consolidated financial statements in our 2014 Annual Report, except for our significant accounting policies related to marketable securities. During the six months ended June 30 , 2015, we purchased marketable debt securities, which are classified as available-for-sale and carried at fair value in the accompanying condensed consolidated balance sheets. We have classified our investments with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. Unrealized holding gains and losses are deferred within accumulated other comprehensive income ( “ AOCI ” ), net o f applicable taxes, except for when an impairment is determined to be other-than-temporary or the security is divested prior to maturity. Interest earned and realized gains and losses on the sale of our marketable securities are included in interest income and other income and expense, respectively, in the accompanying condensed consolidated statements of operations. We perform ongoing reviews to evaluate whether an unrealized loss on an investment represents an other-than-temporary impairment. An unrealized loss exists when the fair value of an investment is less than its amortized cost. When determining whether an impairment is other-than-temporary, we consider the duration and extent to which the fair value of the investment has been below its cost, the financial condition and near-term prospects of the issuer as expressed by the security’s credit rating and rating outlook, and whether a credit event has occurred, including the failure of the issuer to make scheduled interest or principal payments. Should we intend to sell or determine that we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis, we would consider the loss to be other-than-temporary and charge income in the period such determination is made. For debt securities that we have no intent to sell and for which we believe that it is more likely than not that we will not be required to sell prior to recovery, only the credit loss component of the impairment is charged to income, while any remaining loss remains recognized in AOCI. The credit loss component is identified as the difference between the present value of expected cash flows expected to be collected and the amortized cost of the investment. New Accounting Pronouncements Not Yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued an amendment which will replace most of the existing revenue recognition guidance within U.S. GAAP. The core principle of this guidance is that an entity should recognize revenue for the transfer of goods or services to customers in an amount that it expects to be entitled to receive for those goods or services. In doing so, companies will be required to make certain judgments and estimates, including identifying contract performance obligations, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price among separate performance obligations. Additionally, the amendment requires disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, significant judgments reached in the application of the guidance and assets recognized from the costs to obtain or fulfill a contract. In July 2015, the FASB voted to defer t he effective date of the amendment to apply to public business entities for annual and interim period s ending after December 15, 2017. The amendment all ows for two methods of adoption: a full retrospective method or a modified retrospective approach with the cumulative effect recognized at the date of initial application. We are in the process of determining the method of adoption and the impact of this amendment on our consolidated financial statements. In August 2014, the FASB issued an amendment that requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments in this update provide guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for one year after the date that the financial statements are issued and to provide related footnote disclosures. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments in this update apply to all entities and are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. This amendment is not expected to have a material impact on our financial statements. In February 2015, the FASB issued amendments which change the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities, placing more emphasis on risk of loss when determining a controlling financial interest. The amendments in this update apply to all entities and are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. This amendment is not expected to have a material impact on our financial statements. In April 2015, the FASB issued amendments that require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. Under current guidance, our debt issuance costs are reflected as a deferred charge, within other current assets, net and other long-term assets, net on our condensed consolidated balance sheets. This update is effective for the annual reporting periods beginning after December 15, 2015. This amendment is not expected to have a material impact on our financial statements. In April 2015, the FASB issued amendments that provide guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The new guidance does not change the accounting for a customer’s accounting for service contracts. The standard update is effective for fiscal years beginning after December 15, 2015 and interim periods within those years. Early adoption is permitted. The standard allows for adoption retrospectively or prospectively to all arrangements entered into or materially modified after the effective date. The amendment is not expected to have a material impact on our financial statements. In May 2015, the FASB issued amendments which remove the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value as a practical expedient for fair value. Removing investments measured using the practical expedient from the fair value hierarchy is intended to eliminate the diversity in practice that currently exists with respect to the categorization of these investments. The new guidance requires reporting entities to continue to disclose information on investments for which fair value is measured at net asset value (or its equivalent) as a practical expedient to help users understand the nature and risks of the investments and whether the investments, if sold, are probable of being sold at amounts different from net asset value. A reporting entity should apply the amendments retrospectively to all periods presented. This update is effective for public business entities during fiscal years beginning after December 15, 2015. Early adoption is permitted. This amendment is not expected to have a material impact on our financial statements. In July 2015, the FASB issued amendments which simplify the existing guidance which requires entities to subsequent ly measure inventory at the lower of cost or market value . Under the amendments, a n entity should measure inventory valued using a first-in, first-out or average cost method at the lower of cost and net realizable value, which is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This update is effective for public business entities during fiscal years beginning after December 15, 2016. Early adoption is permitted. This amendment is not expected to have a material impact on our financial statements.

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2015
Share-Based Compensation [Abstract]
Share-Based Compensation	NOTE 3. SHARE-BASED COMPENSATION The fair value of options, restricted stock units, deferred stock units and employee stock purchase rights awarded during the three and six months ended June 30, 2015 totaled $1.8 million and $23.8 million, respectively , as compared to $2.5 million and $22.8 million for the three and six months ended June 30, 2014, respectively . T he total unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensatio n awards outstanding at June 30 , 2015 was $46. 8 million, which will be recognized over a weighted average period of approximately 2. 0 years. We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at each grant date. As such, we may use different assumptions for options granted throughout the year. Option awards are granted with an exercise price equal to the closing market price of our common stock at the date of grant. We have never paid any cash dividends on our common stock, and we have no intention to pay such a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards. The weighted averages of the valuation assumptions used to determine the fair value of each option award on the date of grant and the weighted average estimated fair values were as follows: For the Six Months Ended June 30, Expected stock price volatility % % Expected term, in years 1 Risk-free interest rate % % Weighted average fair value of options granted $ $

Marketable Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2015
Marketable Securities [Abstract]
Marketable Securities	Note 4. marketable securities The amortized cost and fair value of marketable securities were as follows ( in thousands ): As of June 30, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Corporate bonds $ $ $ $ Agency bonds - U.S. government bonds - Commercial paper - - International government bond - Certificate of deposit - - Municipal bond - Total marketable securities $ $ $ $ No marketable securities have been in a continuous unrealized loss position for more than twelve months. The marketable securities held by the Company were high investment grade, and there were no marketable securities that we consider to be other-than-temporarily impaired as of June 30, 2015. Remaining contractual maturities of marketable securities were as follows ( in thousands ): As of June 30, 2015 Amortized Cost Fair Value Due in one year or less $ $ Due after one through two years $ $

Inventories

Inventories	6 Months Ended
	Jun. 30, 2015
Inventories [Abstract]
Inventories	Note 5. Inventories Inventories, which are stated at the lower of cost (first-in, first-out) or market, include material, conversion costs and inbound freight charges. The components of inventories were as follows (in thousands) : June 30, December 31, Raw materials $ $ Work-in-process Finished goods Inventories $ $

Goodwill And Intangible Assets,

Goodwill And Intangible Assets, Net	6 Months Ended
	Jun. 30, 2015
Goodwill And Intangible Assets, Net [Abstract]
Goodwill And Intangible Assets, Net	Note 6. Goodwill and Intangible Assets, NET The decrease in goodwill during the six months ended June 30, 2015 resulted from changes in foreign currency exchange rates. The decrease in intangible assets other than goodwill during the six months ended June 3 0 , 201 5 resulted primarily from the continued amortization of our intangible assets and changes in foreign currency exchange rates.

Other Current And Long-term Ass

Other Current And Long-term Assets	6 Months Ended
	Jun. 30, 2015
Other Current And Noncurrent Assets [Abstract]
Other Current And Noncurrent Assets	NOTE 7. Other current and long-term ASSETS Other current assets , net consisted of the following (in thousands) : June 30, December 31, Prepaid expenses $ $ Taxes receivable Customer acquisition costs, net Other assets Other current assets, net $ $ Other long-term assets , net consisted of the following (in thousands) : June 30, December 31, Investment in long-term product supply arrangements $ $ Customer acquisition costs, net Other assets Other long-term assets, net $ $

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2015
Accrued Liabilities [Abstract]
Accrued Liabilities	Note 8. Accrued liabilities Accrued liabilities consisted of the following (in thousands) : June 30, December 31, Accrued expenses $ $ Accrued employee compensation and related expenses Accrued taxes Accrued customer programs Accrued liabilities $ $

Debt

Debt	6 Months Ended
	Jun. 30, 2015
Debt [Abstract]
Debt	Note 9. Debt In June 2015, we entered into an Amended and Restated Multi-Currency Note Purchase and Private Shelf Agreement (the “Amended Agreement”), among the Company, Prudential Investment Management, Inc. (“Prudential”) and the accredited institutional purchasers named therein, which amends and restates the Note Purchase and Private Shelf Agreement dated July 21, 2014. Pursuant to the Amended Agreement, we issued and sold through a private placement a principal amount of €88 .9 million (approximately $100 million) of 1.785% Series C Senior Notes due June 18, 2025 (the “2025 Notes”). We used the net proceeds from this issuance and sale of the 2025 Notes for general corporate purposes, including repaying amounts outstanding under our revolving credit facility. The Amended Agreement also provides for an uncommitted shelf facility by which we may request that Prudential purchase, over the next three years, up to $75 million (or the foreign currency equivalent) of additional senior promissory notes of the Company at a fixed interest rate and with a maturity date not to exceed twelve years (the “Shelf Notes”). Prudential is under no obligation to purchase any of the Shelf Notes. The interest rate of any series of Shelf Notes will be determined at the time of purchase. The proceeds of any series of Shelf Notes will be used only for general corporate purposes. In December 2014, we entered into a Multi -C urrency Note Purchase and Private Shelf Agreement (the “MetLife Agreement”) with accredited institutional purchasers named therein pursuant to which we agreed to issue and sell $75 million of 3.25% Series A Senior Notes having a seven -year term (the “ 2022 Notes”) and $75 million of 3.72% Series B Senior Notes having a twelve -year term (the “ 2027 Notes”). In February 2015, we issued and sold the 2022 Notes and the 2027 Notes pursuant to the MetLife Agreement. We used the net proceeds from these issuance and sales for general corporate purposes, including repaying amounts outstanding under our revolving credit facility. Since December 2013, we have issued and sold through private placements senior notes that have an aggregate principal amount of approximately $600 million pursuant to certain note purchase agreements (collectively, the “Senior Note Agreements”). The Senior Note A greements contain affirmative, negative and financial covenants customary for agreements of this type. The negative covenants include restrictions on liens, indebtedness of our subsidiaries, priority indebtedness, fundamental changes, investments, transactions with affiliates, certain restrictive agreements and violations of laws and regulations. The financial covenant is a consolidated leverage ratio test that requires our ratio of debt to earnings before interest, taxes, depreciation, amortization and share-based compensation, as defined in the Senior Note A greements, not to exceed 3.5 -to-1. At June 3 0 , 2015 we were in compliance with the covenants of the Senior Note A greements. See Note 10 to the consolidated financial statements in our 2014 Annual Report for additional information regarding our senior notes.

Repurchases Of Common Stock

Repurchases Of Common Stock	6 Months Ended
	Jun. 30, 2015
Repurchases Of Common Stock [Abstract]
Repurchases Of Common Stock	Note 10 . Repurchases of common STOCK The following is a summary of our open market common stock repurchases for the three and six months ended June 30 , 2015 and 2014 (in thousands, except per share amounts) : For the Three Months Ended For the Six Months Ended June 30, June 30, Shares repurchased 1 Total cost of shares repurchased $ $ $ $ Average cost per share 1 $ $ $ $ _____________ (1) Shares repurchased and acquired through employee surrender for payment of minimum required withholding taxes on and before June 15, 2015 and the associated average cost per share have been adjusted to reflect the June 2015 two -for-one stock split. Act ual shares repurchased were approximately 890,000 and 973,000 for the three months ended June 30, 2015 a nd 2014, respectively, and approximately 1,749,000 and 1,549,000 for the six months ended June 30, 2015 and 2014, respectively. We primarily acquire shares by means of repurchases in the open market. However, we also acquire shares that are surrendered by employees in payment for the minimum required withholding taxes due on the vesting of restricted stock units and the settlement of deferred stock units, otherwise referred to herein as employee surrenders. The number of shares acquired through employee surrenders during both the three months ended June 30, 2015 and 2014 was not material. We acquired approximately 64,000 shares having a total cost of $5.1 million in connection with such employee surrenders during the six months ended June 3 0 , 2015 as compared to approximately 84,000 shares having a total cost of $5.2 million during the six months ended June 30 , 2014. In conjunction with a two-for-one split of our outstanding shares of common stock enacted on May 18, 2015, IDEXX paid the stock dividend on June 15, 2015 by issuing approximately 46.6 million shares of treasury stock having a total carrying value of approximately $1.5 billion. We issue shares of treasury stock upon the vesting of certain restricted stock units and upon the exercise of certain stock options. The number of shares of treasury st ock issued during both the six months ended June 30 , 2015 and 2014 was not material.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Taxes [Abstract]
Income Taxes	Note 11 . Income Taxes Our effective income tax rate was 30.2% and 30.3% for the t hree and six months ended June 30, 2015 , respectively , as compared to 29.1% and 30.1% for the three and six months ended June 30, 2014, respectively . The increase in our effective rate for the three and six months ended June 30, 2015 as compared to the same periods of the prior year was related to the resolution of domestic and international tax audits during both the three and six months ending June 30, 2014, which resulted in a net reduction in our provision for income taxes in those periods. This unfavorable factor was partly offset by greater tax benefits related to earnings subject to international tax rates that are lower than domestic tax rates during the three and six months ended June 30, 2015.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	6 Months Ended
	Jun. 30, 2015
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income	Note 1 2 . ACCUMULATED OTHER Comprehensive Income The changes in AOCI , net of tax, for the six months ended June 30 , 2015 consisted of the following (in thousands) : For the Six Months Ended June 30, 2015 Unrealized Gain on Investments, Net of Tax Unrealized Gain on Derivative Instruments, Net of Tax Unrealized Gain on Net Investment Hedge Cumulative Translation Adjustment Total Balance as of December 31, 2014 $ $ $ - $ $ Other comprehensive income (loss) before reclassifications Gains reclassified from accumulated other comprehensive income - - - Balance as of June 30, 2015 $ $ $ $ $ The following is a summary of reclassifications out of AOCI for the three and six months ended June 30 , 2015 and 2014 (in thousands) : Details about AOCI Components Affected Line Item in the Statement Where Net Income is Presented Amounts Reclassified from AOCI For the Three Months Ended June 30, Gains (losses) on derivative instruments classified as cash flow hedges included in net income: Foreign currency exchange contracts Cost of revenue $ $ Interest rate swaps Interest expense Total gains (losses) before tax Tax expense (benefit) Gains (losses), net of tax $ $ Details about AOCI Components Affected Line Item in the Statement Where Net Income is Presented Amounts Reclassified from AOCI For the Six Months Ended June 30, Gains (losses) on derivative instruments classified as cash flow hedges included in net income: Foreign currency exchange contracts Cost of revenue $ $ Interest rate swaps Interest expense Total gains (losses) before tax Tax expense (benefit) Gains (losses), net of tax $ $

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share	Note 1 3 . Earnings per Share Basic earnings per share is computed by dividing net income attributable to IDEXX Laboratories, Inc. stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options, the total unrecognized compensation expense for unvested share-based compensation awards and the excess tax benefits resulting from share-based compensation tax deductions in excess of the related expense recognized for financial reporting purposes, would be used to purchase our common stock at the average market price during the period. Vested deferred stock units outstanding are included in shares outstanding for basic and diluted earnings per share because the associated shares of our common stock are issuable for no cash consideration, the number of shares of our common stock to be issued is fixed and issuance is not contingent. See Note 4 to the consolidated financial statements in our 2014 Annual Report for additional information regarding deferred stock units. The following is a reconciliation of shares outstanding for basic and diluted earnings per share for the three and six months ended June 30 , 2015 and 2014 (in thousands) : For the Three Months Ended For the Six Months Ended June 30, June 30, Shares outstanding for basic earnings per share Shares outstanding for diluted earnings per share: Shares outstanding for basic earnings per share Dilutive effect of share-based payment awards C ertain options to acquire shares and restricted stock units have been excluded from the calculation of shares outstanding for diluted earnings per share because they were anti-dilutive. The following table presents information concerning those anti-dilutive options and restricted stock units for the three and six months ended June 3 0 , 2015 and 2014 (in thousands ): For the Three Months Ended For the Six Months Ended June 30, June 30, Weighted average number of shares underlying anti-dilutive options Weighted average number of shares underlying anti-dilutive restricted stock units

Commitments, Contingencies And

Commitments, Contingencies And Guarantees	6 Months Ended
	Jun. 30, 2015
Commitments, Contingencies And Guarantees [Abstract]
Commitments, Contingencies And Guarantees	Note 14 . Commitments, Contingencies and Guarantees Significant commitments, contingencies and guarantees at June 3 0 , 2015 are consistent with those discussed in Note 13 to the consolidated financial statements in our 2014 Annual Report , with the exception of approximately $250 million of long-term debt issued during the six months ended June 30, 2015. See Note 9 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Segment Reporting	Note 15. Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-maker is our Chief Executive Officer. Our reportable segments include diagnostic and information technology-based products and services for the veterinary market, which we refer to as the Companion Animal Group (“CAG”), water quality products (“Water”) and diagnostic tests for livestock and poultry health and to ensure the quality and safety of milk and food, which we refer to as Livestock, Poultry and Dairy (“LPD”). Our Other operating segment combines and presents products for the human point-of-care medical diagnostics market with our pharmaceutical product line and our out-licensing arrangements because they do not meet the quantitative or qualitative thresholds for reportable segments. Prior to January 1, 2015, our CAG segment included certain livestock testing services processed within and managed by our CAG Reference Laboratories. We have transitioned the responsibility for these diagnostic services to our LPD segment to more effectively align our business with the nature and customers o f these livestock services. S egment revenue and income from operations for the three and six months ended June 30, 2014 has been retrospectively revised in this Quarterly Report on Form 10-Q to reflect this change in the composition of our reportable segments. Revenue related to these livestock testing services was $ 4.6 million and $7.4 million for the three and six months ended June 30, 2014, respectively. Items that are not allocated to our operating segments are as follows: a portion of corporate support function and personnel-related expenses; certain manufacturing costs; corporate research and development expenses that do not align with one of our existing business or service categories; the difference between estimated and actual share-based compensation expense; and certain foreign currency exchange gains and losses. These amounts are shown under the caption “Unallocated Amounts.” We estimate our share-based compensation expense, corporate support function expenses and certain personnel-related costs and allocate the estimated expenses to the operating segments. This allocation differs from actual expense and consequently yields a difference that is reported under the caption “Unallocated Amounts.” With respect to manufacturing costs, the costs reported in our operating segments include our standard cost for products sold and any variances from standard cost for products purchased or manufactured within the period. We capitalize these variances for inventory on hand at the end of the period to record inventory in accordance with U.S. GAAP. We then record these variances as cost of product revenue as that inventory is sold. The impact to cost of product revenue resulting from this variance capitalization and subsequent recognition is reported within the caption “Unallocated Amounts.” Additionally, in certain geographies where we maintain inventories in currencies other than the U.S. dollar, the product costs reported in our operating segments include our standard cost for products sold, which is stated at the budgeted currency exchange rate from the beginning of the fiscal year. In these geographies, the variances from standard cost for products sold related to changes in currency exchange rates are reported within the caption “Unallocated Amounts.” The following is a summary of segment performance for the three and six months ended June 30, 2015 and 2014 (in thousands) : For the Three Months Ended June 30, CAG Water LPD Other Unallocated Amounts Consolidated Total 2015 Revenue $ $ $ $ $ - $ Income (loss) from operations $ $ $ $ $ $ Interest expense, net Income before provision for income taxes Provision for income taxes Net income Less: Net income attributable to noncontrolling interest Net income attributable to IDEXX Laboratories, Inc. stockholders $ 2014 Revenue $ $ $ $ $ - $ Income (loss) from operations $ $ $ $ $ $ Interest expense, net Income before provision for income taxes Provision for income taxes Net income Less: Net income attributable to noncontrolling interest Net income attributable to IDEXX Laboratories, Inc. stockholders $ For the Six Months Ended June 30, CAG Water LPD Other Unallocated Amounts Consolidated Total 2015 Revenue $ $ $ $ $ - $ Income (loss) from operations $ $ $ $ $ $ Interest expense, net Income before provision for income taxes Provision for income taxes Net income Less: Net income attributable to noncontrolling interest Net income attributable to IDEXX Laboratories, Inc. stockholders $ 2014 Revenue $ $ $ $ $ - $ Income (loss) from operations $ $ $ $ $ $ Interest expense, net Income before provision for income taxes Provision for income taxes Net income Less: Net income attributable to noncontrolling interest Net income attributable to IDEXX Laboratories, Inc. stockholders $ The following is a summary of revenue by product and service category for the three and six months ended June 30, 2015 and 2014 ( in thousands ): For the Three Months Ended For the Six Months Ended June 30, June 30, CAG segment revenue: CAG Diagnostics recurring revenue: $ $ $ $ IDEXX VetLab ® consumables VetLab service and accessories Rapid assay products Reference laboratory diagnostic and consulting services CAG Diagnostics capital - instruments Customer information management and digital imaging systems CAG segment revenue Water segment revenue LPD segment revenue Other segment revenue Total revenue $ $ $ $

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2015
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 16 . FAIR VALUE MEASUREMENTS U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. U.S. GAAP requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The Company has certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a nonrecurring basis and certain financial assets and liabilities that are not measured at fair value in our condensed consolidated balance sheets but for which we disclose the fair value. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows : Level 1 Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. We did not have any transfers between Level 1 and Level 2 or transfers in or out of Level 3 of the fair value hierarchy during the six months ended June 30, 2015. Our marketable debt securities are initially valued at the transaction price and are subsequently remeasured to fair value as of the balance sheet date utilizing third party pricing services. The pricing services utilize industry standard valuation models, including both income and market based approaches and observable market inputs to determine value. Observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers and other industry and economic events. We validate the prices provided by our third party pricing services by obtaining independent market values from other pricing sources and analyzing pricing data in certain instances. Our foreign currency exchange contracts and interest rate swap agreements are measured at fair value on a recurring basis in our accompanying condensed consolidated balance sheets. We measure the fair value of our foreign currency exchange contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk. We measure the fair value of our interest rate swaps classified as derivative instruments using an income approach, utilizing a discounted cash flow analysis based on the terms of the contract and the interest rate curve adjusted for counterparty risk. The amount outstanding under our unsecured revolving credit facility (“Credit Facility”) and long-term debt are measured at carrying value in our accompanying condensed consolidated balance sheets though we disclose the fair value of these financial instruments. We determine the fair value of the amount outstanding under our Credit Facility and long-term debt using an income approach, utilizing a discounted cash flow analysis based on current market interest rates for debt issues with similar remaining years to maturity, adjusted for applicable credit risk. Our Credit Facility and l ong-term debt are valued using L evel 2 inputs. The estimated fair value of o ur Credit Facility approximates its carrying value. The estimated fair value and carrying value of our long-term debt were $597.4 million and $5 98.9 million , respectively, as of June 30 , 2015 and $367.3 million and $350.0 million , respectively, as of December 31, 2014. The following tables set forth our assets and liabilities that were measured at fair val ue on a recurring basis at June 3 0 , 2015 and at December 31, 2014 by level within the fair value hierarchy (in thousands) : Quoted Prices Significant in Active Other Significant Markets for Observable Unobservable Identical Assets Inputs Inputs Balance at As of June 30, 2015 (Level 1) (Level 2) (Level 3) June 30, 2015 Assets Money market funds (1) $ $ - $ - $ Commercial paper (1) - - Marketable Securities Corporate bonds - - Agency bonds - - U.S. government bonds - - Commercial paper (1) - - International government bond - - Certificate of deposit - - Municipal bond - - Total marketable securities - - Equity mutual funds (2) - - Foreign currency exchange contracts (3) - - Liabilities Foreign currency exchange contracts (3) - - Deferred compensation (4) - - Interest rate swaps (5) - - Quoted Prices Significant in Active Other Significant Markets for Observable Unobservable Identical Assets Inputs Inputs Balance at As of December 31, 2014 (Level 1) (Level 2) (Level 3) December 31, 2014 Assets Money market funds (1) $ $ - $ - $ Equity mutual funds (2) - - Foreign currency exchange contracts (3) - - Liabilities Foreign currency exchange contracts (3) - - Deferred compensation (4) - - Interest rate swaps (5) - - _____________ (1) Money market funds and commercial paper with an original maturity of less than ninety days are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of June 30, 2015 and December 31, 2014 consisted of demand deposits. Commercial paper with an original maturity of over ninety days is included within marketable securities. (2) Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other long-term assets, net. See number (4) below for a discussion of the related deferred compensation liability. (3) Foreign currency exchange contracts are included within other current assets , net ; other long-term assets, net; accrued liabilities; or other long-term liabilities depending on the gain (loss) position and anticipated settlement date. (4) A deferred compensation plan assumed as part of a previous business combination is included within accrued liabilities and other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in number (2) above. (5) Interest rate swaps are included within accrued liabilities. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate carrying value due to their short maturity.

Hedging Instruments

Hedging Instruments	6 Months Ended
	Jun. 30, 2015
Hedging Instruments [Abstract]
Hedging Instruments	Note 17 . HEDGING Instruments Disclosure within this footnote is presented to provide transparency about how and why we use derivative and non-derivative instruments (collectively ‘hedging instruments’) , how the instruments and related hedged items are accounted for, and how the instruments and related hedged items affect our financial position, results of operations and cash flows. We are exposed to certain risks related to our ongoing business operations. The primary risks that we manage by using hedging instruments are foreign currency exchange risk and interest rate risk. Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk associated with their forecasted intercompany inventory purchases and sales for the next year. From time to time, we may also enter into other foreign currency exchange contracts or foreign-denominated debt issuances to minimize the impact of foreign currency fluctuations associated with specific balance sheet exposures , including net investments in certain foreign subsidiaries . We enter into interest rate swaps to minimize the impact of interest rate fluctuations associated with borrowings under our variable-rate Credit Facility. The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions, including transactions denominated in euro, British pound, Japanese yen, Canadian dollar, Australian dollar and Swiss franc. We also utilize natural hedges to mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of allowable hedging activity. We enter into foreign curre ncy exchange contracts with well-capitalized multinational financial institutions, and we do not hold or engage in transactions involving derivative instruments for purposes other than risk management. We recognize all hedging instruments on the balance sheet at fair value at the balance sheet date. I nstruments that do not qualify for hedge accounting treatment must be recorded at fair value through earnings. To qualify for hedge accounting treatment, cash flow and net investment hedges must be highly effective in offsetting changes to expected future cas h flows or fair value on hedged transactions. If the instrument qualifies for hedge accounting, c hanges in the fair value of the hedging instrument from the effective portion of the hedge are deferred in AOCI, net of tax, and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We immediately record in earn ings the extent to which a hedging instrument is not effective in achieving offsetting changes in fair value. We de-designate hedging instruments from hedge accounting when the likelihood of the hedged transaction occurring becomes less than probable. For de-designated instruments, the gain or loss from the time of de-designation through maturity of the instrument is recognized in earnings. Any gain or loss in AOCI at the time of de-designation is reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. See Note 1 2 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for further information regarding the effect of hedging instruments on the condensed consolidated statements of operations for the three and six months ended June 30 , 2015 and 2014. We enter into master netting arrangements with the counterparties to our derivative transactions which permit certain outstanding receivables and payables to be offset in the event of default. Our derivative contracts do not require either party to post cash collateral. We elect to present our derivative assets and liabilities in the accompanying condensed consolidated balance sheets on a gross basis. All cash flows related to our foreign currency exchange contracts and interest rate swaps are classified as operating cash flows, which is consistent with the cash flow treatment of the underlying items being hedged. Cash Flow Hedges We have designated our foreign currency exchange contracts and variable-to-fixed interest rate swaps as cash flow hedges as these derivative instruments mitigate the exposure to variability in the cash flows of forecasted transactions attributable to foreign currency exchange and interest rates. Unless noted otherwise, we have also designated our derivative instruments as qualifying for hedge accounting treatment. We did not de-designate any instruments from hedge accounting treatment during the three and six months ended June 30 , 2015 or 2014. Gains or losses related to hedge ineffectiveness recognized in earnings during the three and six months ended June 3 0 , 2015 and 2014 were not material . At June 30 , 2015, the estimated amount of net gains, net of income tax expense, which are expected to be reclassified out of AOCI and into earnings within the next 12 months, is $5.8 million if exchange and interest rates do not fluctuate from the levels at June 30 , 2015. We enter into foreign currency exchange contracts for amounts that are less than the full value of forecasted intercompany inventory purchases and sales. Our hedging strategy related to intercompany inventory purchases and sales is to employ the full amount of our planned hedges for the succeeding year at the conclusion of our budgeting process for that year. We primarily utilize foreign currency exchange contracts with durations of less than 24 months. Quarterly, we enter into contracts to hedge incremental portions of anticipated foreign currency transactions for the current and following year. As a result, our risk with respect to foreign currency exchange rate fluctuations and the notional value of foreign currency exchange contracts may vary throughout the year. The U.S. dollar is the currency purchased or sold in all of our foreign currency exchange contracts. The notional amount of foreign currency exchange contracts to hedge forecasted intercompany inventory purchases and sales totaled $203.8 million and $186.7 million at June 3 0 , 2015 and December 31, 2014, respectively. We have entered into forward fixed interest rate swap agreements to manage the economic effect of variable interest obligations on amounts borrowed under the terms of our Credit Facility. Beginning on March 30, 2012, the variable interest rate associated with $40 million of borrowings outstanding under the Credit Facility became effectively fixed at 1.36% plus the ra nge of applicable interest rate fixed credit spreads (“Credit Spread”) through June 30, 2016. Beginning on March 28, 2013, the variable interest rate associated with an additional $40 million of borrowings outstanding under the Credit Facility became effectively fixed at 1.64% plus the Credit Spread through June 30, 2016. Net Investment Hedge In June 2015, we issued and sold through a private placement an aggregate principal amount of €88.9 million (approximately USD $100 million) in euro-denominated 1.785% Series C Senior Notes due June 18, 2025. We have designated these euro-denominated notes as a hedge of our euro net investment in certain foreign subsidiaries to reduce the volatility in stockholders’ equity caused by changes in foreign currency exchange rates in the euro relative to the U.S. dollar. As a result of this designation, gains and losses from the change in translated U.S. dollar value of these euro-denominated notes are recorded in AOCI rather than to earnings. We recorded a $0.7 million gain, net of income tax, within AOCI as a result of this net investment hedge for both the three and six months ended June 30, 2015. This unrealized gain will not be reclassified in earnings until the complete or substantially complete liquidation of the net investment in the hedged foreign operations, all or a portion of the hedge no longer qualifies for hedge accounting treatment or repayment of the loan in full. See Note 9 to the condensed consolidated financial statements including in this Quarterly Report on Form 10-Q for further information regarding the issuance of these euro-denominated notes. Fair Values of Hedging Instruments Designated as Hedges in Consolidated Balance Sheets The fair values of hedging instruments and their respective classification on the condensed consolidated balance sheets and amounts subject to offset under master netting arrangements consisted of the following (in thousands) : Hedging Assets June 30, December 31, Derivatives designated as hedging instruments Balance Sheet Classification Foreign currency exchange contracts Other current assets $ $ Foreign currency exchange contracts Other long-term assets, net - Total derivative instruments presented as cash flow hedges on the balance sheet Gross amounts subject to master netting arrangements not offset on the balance sheet Net amount $ $ Hedging Liabilities June 30, December 31, Derivatives designated as hedging instruments Balance Sheet Classification Foreign currency exchange contracts Accrued liabilities $ $ Foreign currency exchange contracts Other long-term liabilities - Interest rate swaps Accrued liabilities Total derivative instruments presented as cash flow hedges on the balance sheet Foreign currency borrowings designated as net investment hedge on the balance sheet Long-term debt - Total hedging instruments presented on the balance sheet Gross amounts subject to master netting arrangements not offset on the balance sheet Net amount $ $ The effect of derivative instruments designated as cash flow hedges on the condensed consolidated balance sheets consisted of the following (in thousands) : (Loss) Gain Recognized in AOCI on Derivative Instruments (Effective Portion) For the Three Months Ended For the Six Months Ended June 30, June 30, Derivative instruments Cash flow hedging derivatives: Foreign currency exchange contracts, net of tax $ $ $ $ Interest rate swaps, net of tax Total cash flow hedges $ $ $ $

Share-Based Compensation (Polic

Share-Based Compensation (Policy)	6 Months Ended
	Jun. 30, 2015
Share-Based Compensation [Abstract]
Share-Based Compensation Policy	We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at each grant date. As such, we may use different assumptions for options granted throughout the year. Option awards are granted with an exercise price equal to the closing market price of our common stock at the date of grant. We have never paid any cash dividends on our common stock, and we have no intention to pay such a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards.

Inventories (Policy)

Inventories (Policy)	6 Months Ended
	Jun. 30, 2015
Inventories [Abstract]
Inventories Policy	Inventories, which are stated at the lower of cost (first-in, first-out) or market, include material, conversion costs and inbound freight charges.

Earnings Per Share (Policy)

Earnings Per Share (Policy)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share Policy	Basic earnings per share is computed by dividing net income attributable to IDEXX Laboratories, Inc. stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options, the total unrecognized compensation expense for unvested share-based compensation awards and the excess tax benefits resulting from share-based compensation tax deductions in excess of the related expense recognized for financial reporting purposes, would be used to purchase our common stock at the average market price during the period. Vested deferred stock units outstanding are included in shares outstanding for basic and diluted earnings per share because the associated shares of our common stock are issuable for no cash consideration, the number of shares of our common stock to be issued is fixed and issuance is not contingent.

Fair Value Measurements (Policy

Fair Value Measurements (Policy)	6 Months Ended
	Jun. 30, 2015
Fair Value Measurements [Abstract]
Fair Value Measurements Policy	U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. U.S. GAAP requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The Company has certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a nonrecurring basis and certain financial assets and liabilities that are not measured at fair value in our condensed consolidated balance sheets but for which we disclose the fair value. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows : Level 1 Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. We did not have any transfers between Level 1 and Level 2 or transfers in or out of Level 3 of the fair value hierarchy during the six months ended June 30, 2015. Our marketable debt securities are initially valued at the transaction price and are subsequently remeasured to fair value as of the balance sheet date utilizing third party pricing services. The pricing services utilize industry standard valuation models, including both income and market based approaches and observable market inputs to determine value. Observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers and other industry and economic events. We validate the prices provided by our third party pricing services by obtaining independent market values from other pricing sources and analyzing pricing data in certain instances. Our foreign currency exchange contracts and interest rate swap agreements are measured at fair value on a recurring basis in our accompanying condensed consolidated balance sheets. We measure the fair value of our foreign currency exchange contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk. We measure the fair value of our interest rate swaps classified as derivative instruments using an income approach, utilizing a discounted cash flow analysis based on the terms of the contract and the interest rate curve adjusted for counterparty risk. The amount outstanding under our unsecured revolving credit facility (“Credit Facility”) and long-term debt are measured at carrying value in our accompanying condensed consolidated balance sheets though we disclose the fair value of these financial instruments. We determine the fair value of the amount outstanding under our Credit Facility and long-term debt using an income approach, utilizing a discounted cash flow analysis based on current market interest rates for debt issues with similar remaining years to maturity, adjusted for applicable credit risk. Our Credit Facility and l ong-term debt are valued using L evel 2 inputs.

Hedging Instruments (Policy)

Hedging Instruments (Policy)	6 Months Ended
	Jun. 30, 2015
Hedging Instruments [Abstract]
Derivative Instruments And Hedging Policy	We are exposed to certain risks related to our ongoing business operations. The primary risks that we manage by using hedging instruments are foreign currency exchange risk and interest rate risk. Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk associated with their forecasted intercompany inventory purchases and sales for the next year. From time to time, we may also enter into other foreign currency exchange contracts or foreign-denominated debt issuances to minimize the impact of foreign currency fluctuations associated with specific balance sheet exposures , including net investments in certain foreign subsidiaries . We enter into interest rate swaps to minimize the impact of interest rate fluctuations associated with borrowings under our variable-rate Credit Facility. The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions, including transactions denominated in euro, British pound, Japanese yen, Canadian dollar, Australian dollar and Swiss franc. We also utilize natural hedges to mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of allowable hedging activity. We enter into foreign curre ncy exchange contracts with well-capitalized multinational financial institutions, and we do not hold or engage in transactions involving derivative instruments for purposes other than risk management. We recognize all hedging instruments on the balance sheet at fair value at the balance sheet date. I nstruments that do not qualify for hedge accounting treatment must be recorded at fair value through earnings. To qualify for hedge accounting treatment, cash flow and net investment hedges must be highly effective in offsetting changes to expected future cas h flows or fair value on hedged transactions. If the instrument qualifies for hedge accounting, c hanges in the fair value of the hedging instrument from the effective portion of the hedge are deferred in AOCI, net of tax, and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We immediately record in earn ings the extent to which a hedging instrument is not effective in achieving offsetting changes in fair value. We de-designate hedging instruments from hedge accounting when the likelihood of the hedged transaction occurring becomes less than probable. For de-designated instruments, the gain or loss from the time of de-designation through maturity of the instrument is recognized in earnings. Any gain or loss in AOCI at the time of de-designation is reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. See Note 1 2 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for further information regarding the effect of hedging instruments on the condensed consolidated statements of operations for the three and six months ended June 30 , 2015 and 2014. We enter into master netting arrangements with the counterparties to our derivative transactions which permit certain outstanding receivables and payables to be offset in the event of default. Our derivative contracts do not require either party to post cash collateral. We elect to present our derivative assets and liabilities in the accompanying condensed consolidated balance sheets on a gross basis. All cash flows related to our foreign currency exchange contracts and interest rate swaps are classified as operating cash flows, which is consistent with the cash flow treatment of the underlying items being hedged. Cash Flow Hedges We have designated our foreign currency exchange contracts and variable-to-fixed interest rate swaps as cash flow hedges as these derivative instruments mitigate the exposure to variability in the cash flows of forecasted transactions attributable to foreign currency exchange and interest rates. Unless noted otherwise, we have also designated our derivative instruments as qualifying for hedge accounting treatment.

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Share-Based Compensation [Abstract]
Schedule Of Weighted Averages Of The Assumptions Used In Estimating The Fair Value Of Stock Option Awards	For the Six Months Ended June 30, Expected stock price volatility % % Expected term, in years 1 Risk-free interest rate % % Weighted average fair value of options granted $ $

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2015
Marketable Securities [Abstract]
Amortized Cost And Fair Value Of Marketable Securities	As of June 30, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Corporate bonds $ $ $ $ Agency bonds - U.S. government bonds - Commercial paper - - International government bond - Certificate of deposit - - Municipal bond - Total marketable securities $ $ $ $
Contractual Maturities Of Marketable Securities	As of June 30, 2015 Amortized Cost Fair Value Due in one year or less $ $ Due after one through two years $ $

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2015
Inventories [Abstract]
Schedule Of Components Of Inventories	June 30, December 31, Raw materials $ $ Work-in-process Finished goods Inventories $ $

Other Current And Long-term A33

Other Current And Long-term Assets (Tables)	6 Months Ended
	Jun. 30, 2015
Other Current And Noncurrent Assets [Abstract]
Schedule Of Other Current Assets, Net	June 30, December 31, Prepaid expenses $ $ Taxes receivable Customer acquisition costs, net Other assets Other current assets, net $ $
Schedule Of Other Long-term Assets, Net	June 30, December 31, Investment in long-term product supply arrangements $ $ Customer acquisition costs, net Other assets Other long-term assets, net $ $

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2015
Accrued Liabilities [Abstract]
Schedule Of Accrued Liabilities	June 30, December 31, Accrued expenses $ $ Accrued employee compensation and related expenses Accrued taxes Accrued customer programs Accrued liabilities $ $

Repurchases Of Common Stock (Ta

Repurchases Of Common Stock (Tables)	6 Months Ended
	Jun. 30, 2015
Repurchases Of Common Stock [Abstract]
Schedule Of Common Stock Repurchases	For the Three Months Ended For the Six Months Ended June 30, June 30, Shares repurchased 1 Total cost of shares repurchased $ $ $ $ Average cost per share 1 $ $ $ $ _____________ (1) Shares repurchased and acquired through employee surrender for payment of minimum required withholding taxes on and before June 15, 2015 and the associated average cost per share have been adjusted to reflect the June 2015 two -for-one stock split. Act ual shares repurchased were approximately 890,000 and 973,000 for the three months ended June 30, 2015 a nd 2014, respectively, and approximately 1,749,000 and 1,549,000 for the six months ended June 30, 2015 and 2014, respectively.

Accumulated Other Comprehensi36

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2015
Accumulated Other Comprehensive Income [Abstract]
Schedule Of Accumulated Other Comprehensive Income	For the Six Months Ended June 30, 2015 Unrealized Gain on Investments, Net of Tax Unrealized Gain on Derivative Instruments, Net of Tax Unrealized Gain on Net Investment Hedge Cumulative Translation Adjustment Total Balance as of December 31, 2014 $ $ $ - $ $ Other comprehensive income (loss) before reclassifications Gains reclassified from accumulated other comprehensive income - - - Balance as of June 30, 2015 $ $ $ $ $
Summary Of Reclassifications Out Of Accumulated Other Comprehensive Income	Details about AOCI Components Affected Line Item in the Statement Where Net Income is Presented Amounts Reclassified from AOCI For the Three Months Ended June 30, Gains (losses) on derivative instruments classified as cash flow hedges included in net income: Foreign currency exchange contracts Cost of revenue $ $ Interest rate swaps Interest expense Total gains (losses) before tax Tax expense (benefit) Gains (losses), net of tax $ $ Details about AOCI Components Affected Line Item in the Statement Where Net Income is Presented Amounts Reclassified from AOCI For the Six Months Ended June 30, Gains (losses) on derivative instruments classified as cash flow hedges included in net income: Foreign currency exchange contracts Cost of revenue $ $ Interest rate swaps Interest expense Total gains (losses) before tax Tax expense (benefit) Gains (losses), net of tax $ $

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Schedule Of Reconciliation Of Shares Outstanding For Basic And Diluted Earnings Per Share	For the Three Months Ended For the Six Months Ended June 30, June 30, Shares outstanding for basic earnings per share Shares outstanding for diluted earnings per share: Shares outstanding for basic earnings per share Dilutive effect of share-based payment awards
Schedule Of Number Of Anti-Dilutive Stock Options And Restricted Stock Units	For the Three Months Ended For the Six Months Ended June 30, June 30, Weighted average number of shares underlying anti-dilutive options Weighted average number of shares underlying anti-dilutive restricted stock units

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Summary Of Segment Performance	For the Three Months Ended June 30, CAG Water LPD Other Unallocated Amounts Consolidated Total 2015 Revenue $ $ $ $ $ - $ Income (loss) from operations $ $ $ $ $ $ Interest expense, net Income before provision for income taxes Provision for income taxes Net income Less: Net income attributable to noncontrolling interest Net income attributable to IDEXX Laboratories, Inc. stockholders $ 2014 Revenue $ $ $ $ $ - $ Income (loss) from operations $ $ $ $ $ $ Interest expense, net Income before provision for income taxes Provision for income taxes Net income Less: Net income attributable to noncontrolling interest Net income attributable to IDEXX Laboratories, Inc. stockholders $ For the Six Months Ended June 30, CAG Water LPD Other Unallocated Amounts Consolidated Total 2015 Revenue $ $ $ $ $ - $ Income (loss) from operations $ $ $ $ $ $ Interest expense, net Income before provision for income taxes Provision for income taxes Net income Less: Net income attributable to noncontrolling interest Net income attributable to IDEXX Laboratories, Inc. stockholders $ 2014 Revenue $ $ $ $ $ - $ Income (loss) from operations $ $ $ $ $ $ Interest expense, net Income before provision for income taxes Provision for income taxes Net income Less: Net income attributable to noncontrolling interest Net income attributable to IDEXX Laboratories, Inc. stockholders $
Summary Of Revenue By Product And Service Category	For the Three Months Ended For the Six Months Ended June 30, June 30, CAG segment revenue: CAG Diagnostics recurring revenue: $ $ $ $ IDEXX VetLab ® consumables VetLab service and accessories Rapid assay products Reference laboratory diagnostic and consulting services CAG Diagnostics capital - instruments Customer information management and digital imaging systems CAG segment revenue Water segment revenue LPD segment revenue Other segment revenue Total revenue $ $ $ $

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Measurements [Abstract]
Schedule Of Fair Value Of Assets And Liabilities Measured On Recurring Basis	Quoted Prices Significant in Active Other Significant Markets for Observable Unobservable Identical Assets Inputs Inputs Balance at As of June 30, 2015 (Level 1) (Level 2) (Level 3) June 30, 2015 Assets Money market funds (1) $ $ - $ - $ Commercial paper (1) - - Marketable Securities Corporate bonds - - Agency bonds - - U.S. government bonds - - Commercial paper (1) - - International government bond - - Certificate of deposit - - Municipal bond - - Total marketable securities - - Equity mutual funds (2) - - Foreign currency exchange contracts (3) - - Liabilities Foreign currency exchange contracts (3) - - Deferred compensation (4) - - Interest rate swaps (5) - - Quoted Prices Significant in Active Other Significant Markets for Observable Unobservable Identical Assets Inputs Inputs Balance at As of December 31, 2014 (Level 1) (Level 2) (Level 3) December 31, 2014 Assets Money market funds (1) $ $ - $ - $ Equity mutual funds (2) - - Foreign currency exchange contracts (3) - - Liabilities Foreign currency exchange contracts (3) - - Deferred compensation (4) - - Interest rate swaps (5) - - _____________ (1) Money market funds and commercial paper with an original maturity of less than ninety days are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of June 30, 2015 and December 31, 2014 consisted of demand deposits. Commercial paper with an original maturity of over ninety days is included within marketable securities. (2) Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other long-term assets, net. See number (4) below for a discussion of the related deferred compensation liability. (3) Foreign currency exchange contracts are included within other current assets , net ; other long-term assets, net; accrued liabilities; or other long-term liabilities depending on the gain (loss) position and anticipated settlement date. (4) A deferred compensation plan assumed as part of a previous business combination is included within accrued liabilities and other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in number (2) above. (5) Interest rate swaps are included within accrued liabilities.

Hedging Instruments (Tables)

Hedging Instruments (Tables)	6 Months Ended
	Jun. 30, 2015
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain/(Loss) Recognized In Other Comprehensive Income On Derivative Instruments (Effective Portion)	(Loss) Gain Recognized in AOCI on Derivative Instruments (Effective Portion) For the Three Months Ended For the Six Months Ended June 30, June 30, Derivative instruments Cash flow hedging derivatives: Foreign currency exchange contracts, net of tax $ $ $ $ Interest rate swaps, net of tax Total cash flow hedges $ $ $ $
Assets [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments	Hedging Assets June 30, December 31, Derivatives designated as hedging instruments Balance Sheet Classification Foreign currency exchange contracts Other current assets $ $ Foreign currency exchange contracts Other long-term assets, net - Total derivative instruments presented as cash flow hedges on the balance sheet Gross amounts subject to master netting arrangements not offset on the balance sheet Net amount $ $
Liabilities [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments	Hedging Liabilities June 30, December 31, Derivatives designated as hedging instruments Balance Sheet Classification Foreign currency exchange contracts Accrued liabilities $ $ Foreign currency exchange contracts Other long-term liabilities - Interest rate swaps Accrued liabilities Total derivative instruments presented as cash flow hedges on the balance sheet Foreign currency borrowings designated as net investment hedge on the balance sheet Long-term debt - Total hedging instruments presented on the balance sheet Gross amounts subject to master netting arrangements not offset on the balance sheet Net amount $ $

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-Based Compensation [Abstract]
Fair value of share-based compensation awards, granted	$ 1.8	$ 2.5	$ 23.8	$ 22.8
Unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensation awards outstanding	$ 46.8		$ 46.8
Weighted average recognition period for unrecognized compensation expense, in years			2 years

Share-Based Compensation (Sched

Share-Based Compensation (Schedule Of Weighted Averages Of The Assumptions Used In Estimating The Fair Value Of Stock Option Awards) (Details) - $ / shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Share-Based Compensation [Abstract]
Expected stock price volatility	23.00%	28.00%
Expected term, in years	5 years 7 months 6 days	5 years 8 months 12 days
Risk-free interest rate	1.50%	1.50%
Weighted average estimated fair value of options granted	$ 19.72	$ 18.07

Marketable Securities (Amortize

Marketable Securities (Amortized Cost And Fair Value Of Marketable Securities) (Details) - Jun. 30, 2015 - USD ($) $ in Thousands	Total
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 181,011
Gross Unrealized Gains	19
Gross Unrealized Losses	(160)
Fair Value	180,870
Marketable securities have been in a continuous unrealized loss position for more than twelve months	0
Marketable securities that we consider to be other-than-temporarily impaired	0
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	143,233
Gross Unrealized Gains	12
Gross Unrealized Losses	(157)
Fair Value	143,088
Agency Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	18,150
Gross Unrealized Gains	1
Fair Value	18,151
U.S. Government Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	10,211
Gross Unrealized Gains	4
Fair Value	10,215
Commercial Paper Not Included [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	3,747
Fair Value	3,747
International Government Bond [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	2,270
Gross Unrealized Losses	(3)
Fair Value	2,267
Certificate Of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	2,000
Fair Value	2,000
Municipal Bond [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,400
Gross Unrealized Gains	2
Fair Value	$ 1,402

Marketable Securities (Contract

Marketable Securities (Contractual Maturities Of Marketable Securities) (Details) $ in Thousands	Jun. 30, 2015USD ($)
Marketable Securities [Abstract]
Due in one year or less, Amortized Cost	$ 114,841
Due after one through two years, Amortized Cost	66,170
Total marketable securities, Amortized Cost	181,011
Due in one year or less, Fair Value	114,783
Due after one through two years, Fair Value	66,087
Total marketable securities, Fair Value	$ 180,870

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Inventories [Abstract]
Raw materials	$ 30,471	$ 26,908
Work-in-process	20,254	16,859
Finished goods	133,775	116,575
Inventories	$ 184,500	$ 160,342

Other Current And Long-term A46

Other Current And Long-term Assets (Schedule Of Other Current Assets, Net) (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Other Current And Noncurrent Assets [Abstract]
Prepaid expenses	$ 30,378	$ 32,672
Taxes receivable	12,906	28,926
Customer acquisition costs, net	14,230	11,262
Other assets	10,045	13,591
Other current assets, net	$ 67,559	$ 86,451

Other Current And Long-term A47

Other Current And Long-term Assets (Schedule Of Other Long-term Assets, Net) (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Other Current And Noncurrent Assets [Abstract]
Investment in long-term product supply arrangements	$ 12,165	$ 10,765
Customer acquisition costs, net	36,774	28,165
Other assets	32,134	32,724
Other long-term assets, net	$ 81,073	$ 71,654

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Accrued Liabilities [Abstract]
Accrued expenses	$ 62,822	$ 55,655
Accrued employee compensation and related expenses	53,483	75,232
Accrued taxes	29,334	28,439
Accrued customer programs	44,802	36,025
Accrued liabilities	$ 190,441	$ 195,351

Debt (Details)

Debt (Details) € in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2015EUR (€)	Dec. 31, 2014USD ($)	Jun. 30, 2015USD ($)
Senior Notes [Member]
Debt Instrument [Line Items]
Senior Note Agreements, aggregate principal amount			$ 600,000,000
Senior notes payable, consolidated leverage ratio, maximum	3.5
Series A Senior Notes [Member]
Debt Instrument [Line Items]
Senior notes payable		$ 75,000,000
Senior notes payable, stated interest rate		3.25%
Senior notes payable, term		7 years
Series B Senior Notes [Member]
Debt Instrument [Line Items]
Senior notes payable		$ 75,000,000
Senior notes payable, stated interest rate		3.72%
Senior notes payable, term		12 years
Series C Senior Note [Member]
Debt Instrument [Line Items]
Senior notes payable	€ 88.9		$ 100,000,000
Senior notes payable, stated interest rate	1.785%		1.785%
Shelf Notes [Member]
Debt Instrument [Line Items]
Senior notes payable			$ 75,000,000
Senior notes payable, term	12 years

Repurchases Of Common Stock (De

Repurchases Of Common Stock (Details) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)$ / sharesshares
Shares repurchased	1,415,000	1,947,000	3,133,000	3,099,000
Total cost of shares repurchased | $	$ 93,461	$ 126,347	$ 227,108	$ 196,626
Average cost per share | $ / shares	$ 66.07	$ 64.88	$ 72.50	$ 63.45
Stock split			2
Shares acquired through employee surrenders			64,000	84,000
Cost of shares acquired through employee surrenders | $			$ 5,100	$ 5,200
Shares of treasury stock issued			46,600,000
Carrying value of treasury stock, issued | $			$ 1,500,000
Prior To Stock Split [Member]
Shares repurchased	890,000	973,000	1,749,000	1,549,000

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Taxes [Abstract]
Effective Tax Rate	30.20%	29.10%	30.30%	30.10%

Accumulated Other Comprehensi52

Accumulated Other Comprehensive Income (Schedule Of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Accumulated Other Comprehensive Income [Abstract]
Beginning balance, Unrealized Gain on Investments, Net of Tax			$ 1
Beginning balance, Unrealized Gain on Derivative Instruments, Net of Tax			$ 7,361
Beginning balance, Unrealized Gain on Net Investment Hedge, Net of Tax
Beginning balance, Cumulative Translation Adjustment			$ (15,433)
Other comprehensive income (loss) before reclassifications, Unrealized Gain on Investments, Net of Tax	$ (26)	$ 59	7	$ 5
Other comprehensive income (loss) before reclassifications, Unrealized Gain on Derivative Instruments, Net of Tax	(2,885)	(1,924)	4,300	(2,177)
Other comprehensive income (loss) before reclassifications, Unrealized Gain on Net Investment Hedge, Net of Tax	737		737
Other comprehensive income (loss) before reclassifications, Cumulative Translation Adjustment	7,298	2,200	(12,934)	3,479
Gains reclassified from accumulated other comprehensive income, Unrealized Gain on Derivative Instruments, Net of Tax	(3,350)	$ 251	(6,314)	$ 102
Ending balance, Unrealized Gain on Investments, Net of Tax	8		8
Ending balance, Unrealized Gain on Derivative Instruments, Net of Tax	5,347		5,347
Ending balance, Unrealized Gain on Net Investment Hedge, Net of Tax	737		737
Ending balance, Cumulative Translation Adjustment	(28,367)		(28,367)
Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance			(8,071)
Other comprehensive income (loss) before reclassifications	(7,890)		(7,890)
Gains reclassified from accumulated other comprehensive income			(6,314)
Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance	$ (22,275)		$ (22,275)

Accumulated Other Comprehensi53

Accumulated Other Comprehensive Income (Schedule of Reclassifications out of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Tax expense (benefit)	$ 24,665	$ 23,498	$ 45,011	$ 44,648
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax			6,314
Reclassifications out of Accumulated Other Comprehensive Income [Member]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	4,801	(389)	9,018	(193)
Tax expense (benefit)	1,451	(138)	2,704	(91)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	3,350	(251)	6,314	(102)
Foreign Currency Exchange Contracts [Member] | Reclassifications out of Accumulated Other Comprehensive Income [Member]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	5,066	(124)	9,545	334
Interest Rate Swaps [Member] | Reclassifications out of Accumulated Other Comprehensive Income [Member]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	$ (265)	$ (265)	$ (527)	$ (527)

Earnings Per Share (Schedule Of

Earnings Per Share (Schedule Of Reconciliation Of Shares Outstanding For Basic And Diluted Earnings Per Share) (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share [Abstract]
Shares outstanding for basic earnings per share	93,384	102,250	93,829	102,739
Dilutive effect of share-based payment awards	922	1,340	1,105	1,421
Shares outstanding for diluted earnings per share	94,306	103,590	94,934	104,160

Earnings Per Share (Schedule 55

Earnings Per Share (Schedule Of Number Of Anti-Dilutive Stock Options And Restricted Stock Units) (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Stock Options [Member]
Antidilutive Securities [Line Items]
Weighted average number of shares underlying anti-dilutive options	995	701	756	569
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities [Line Items]
Weighted average number of shares underlying anti-dilutive options	131	0	99	0

Commitments, Contingencies An56

Commitments, Contingencies And Guarantees (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Commitments, Contingencies And Guarantees [Abstract]
Issuance of long term debt	$ 250,097

Segment Reporting (Narrative) (

Segment Reporting (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Revenue	$ 413,343	$ 390,122	$ 795,820	$ 750,325
Income from operations	$ 88,303	83,219	$ 161,106	153,265
CAG/LPD Segment Transition [Member]
Segment Reporting Information [Line Items]
Revenue		$ 4,600		$ 7,400

Segment Reporting (Summary Of S

Segment Reporting (Summary Of Segment Performance) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Revenue	$ 413,343	$ 390,122	$ 795,820	$ 750,325
Income (loss) from operations	88,303	83,219	161,106	153,265
Interest expense, net	(6,700)	(2,477)	(12,579)	(4,780)
Income before provision for income taxes	81,603	80,742	148,527	148,485
Provision for income taxes	24,665	23,498	45,011	44,648
Net income	56,938	57,244	103,516	103,837
Less: Net loss attributable to noncontrolling interest	26	26	10	34
Net income attributable to IDEXX Laboratories, Inc. stockholders	56,912	57,218	103,506	103,803
CAG Segment [Member]
Segment Reporting Information [Line Items]
Revenue	351,620	322,129	676,151	620,857
Income (loss) from operations	67,875	66,924	120,304	120,928
Water Segment [Member]
Segment Reporting Information [Line Items]
Revenue	25,051	24,487	46,749	45,908
Income (loss) from operations	11,954	10,064	21,413	18,180
LPD Segment [Member]
Segment Reporting Information [Line Items]
Revenue	32,059	37,307	63,329	71,518
Income (loss) from operations	5,895	10,747	11,846	19,067
Other Segment [Member]
Segment Reporting Information [Line Items]
Revenue	4,613	6,199	9,591	12,042
Income (loss) from operations	(237)	(249)	(431)	340
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Income (loss) from operations	$ 2,816	$ (4,267)	$ 7,974	$ (5,250)

Segment Reporting (Summary Of R

Segment Reporting (Summary Of Revenue By Product And Service Category) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Revenue	$ 413,343	$ 390,122	$ 795,820	$ 750,325
CAG Diagnostics Recurring Revenue [Member]
Segment Reporting Information [Line Items]
Revenue	300,146	276,949	578,911	532,830
IDEXX VetLab Consumables [Member]
Segment Reporting Information [Line Items]
Revenue	100,743	89,113	199,135	173,434
VetLab Service and Accessories [Member]
Segment Reporting Information [Line Items]
Revenue	14,018	13,433	27,548	26,504
Rapid Assay Products [Member]
Segment Reporting Information [Line Items]
Revenue	52,182	49,493	95,819	92,552
Reference Laboratory Diagnostic And Consulting Services [Member]
Segment Reporting Information [Line Items]
Revenue	133,203	124,910	256,409	240,340
CAG Diagnostics Capital - Instruments [Member]
Segment Reporting Information [Line Items]
Revenue	24,064	18,993	44,178	37,580
Customer Information Managment and Digital Imaging Systems [Member]
Segment Reporting Information [Line Items]
Revenue	27,410	26,187	53,062	50,447
CAG Segment [Member]
Segment Reporting Information [Line Items]
Revenue	351,620	322,129	676,151	620,857
Water Segment [Member]
Segment Reporting Information [Line Items]
Revenue	25,051	24,487	46,749	45,908
LPD Segment [Member]
Segment Reporting Information [Line Items]
Revenue	32,059	37,307	63,329	71,518
Other Segment [Member]
Segment Reporting Information [Line Items]
Revenue	$ 4,613	$ 6,199	$ 9,591	$ 12,042

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, carrying value	$ 598,925	$ 350,000
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, fair value	$ 597,400	$ 367,300

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule Of Fair Value Of Assets And Liabilities Measured On Recurring Basis) (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	$ 180,870
Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	143,088
Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	18,151
U.S. Government Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	10,215
Commercial Paper Not Included [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	3,747
International Government Bond [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	2,267
Certificate Of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	2,000
Municipal Bond [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	1,402
Measured At Fair Value On Recurring Basis [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	180,870
Measured At Fair Value On Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	180,870
Measured At Fair Value On Recurring Basis [Member] | Equity Mutual Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,556	$ 2,654
Measured At Fair Value On Recurring Basis [Member] | Equity Mutual Funds [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,556	2,654
Measured At Fair Value On Recurring Basis [Member] | Foreign Currency Exchange Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	10,349	12,226
Fair value of Liabilities	2,109	1,323
Measured At Fair Value On Recurring Basis [Member] | Foreign Currency Exchange Contracts [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	10,349	12,226
Fair value of Liabilities	2,109	1,323
Measured At Fair Value On Recurring Basis [Member] | Deferred Compensation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	2,556	2,654
Measured At Fair Value On Recurring Basis [Member] | Deferred Compensation [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	2,556	2,654
Measured At Fair Value On Recurring Basis [Member] | Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	870	1,117
Measured At Fair Value On Recurring Basis [Member] | Interest Rate Swaps [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	870	1,117
Measured At Fair Value On Recurring Basis [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	30,384	204,743
Measured At Fair Value On Recurring Basis [Member] | Money Market Funds [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	30,384	$ 204,743
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	9,747
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	9,747
Measured At Fair Value On Recurring Basis [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	143,088
Measured At Fair Value On Recurring Basis [Member] | Corporate Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	143,088
Measured At Fair Value On Recurring Basis [Member] | Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	18,151
Measured At Fair Value On Recurring Basis [Member] | Agency Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	18,151
Measured At Fair Value On Recurring Basis [Member] | U.S. Government Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	10,215
Measured At Fair Value On Recurring Basis [Member] | U.S. Government Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	10,215
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper Not Included [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	3,747
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper Not Included [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	3,747
Measured At Fair Value On Recurring Basis [Member] | International Government Bond [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	2,267
Measured At Fair Value On Recurring Basis [Member] | International Government Bond [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	2,267
Measured At Fair Value On Recurring Basis [Member] | Certificate Of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	2,000
Measured At Fair Value On Recurring Basis [Member] | Certificate Of Deposit [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	2,000
Measured At Fair Value On Recurring Basis [Member] | Municipal Bond [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	1,402
Measured At Fair Value On Recurring Basis [Member] | Municipal Bond [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	$ 1,402

Hedging Instruments (Narrative)

Hedging Instruments (Narrative) (Details) $ in Thousands, € in Millions	6 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2015EUR (€)	Jun. 30, 2015USD ($)	Dec. 31, 2014USD ($)
Derivative [Line Items]
Estimated net amount of gains that are expected to be reclassified out of accumulated other comprehensive income and into earnings within the next 12 months	$ 5,800
General duration of foreign currency exchange contracts	24 months
Notional Amount of Foreign Currency Exchange Contracts			$ 203,800	$ 186,700
Accumulated Other Comprehensive Income (Loss), Net Investment Hedge, Net Of Tax			737
Interest Rate Swap Effective On March 30, 2012 [Member]
Derivative [Line Items]
Credit Facility borrowings hedged			$ 40,000
Fixed portion of interest rate associated with interest rate swap		1.36%	1.36%
Interest Rate Swap Effective On March 28, 2013 [Member]
Derivative [Line Items]
Credit Facility borrowings hedged			$ 40,000
Fixed portion of interest rate associated with interest rate swap		1.64%	1.64%
Series C Senior Note [Member]
Derivative [Line Items]
Senior notes payable		€ 88.9	$ 100,000
Senior notes payable, stated interest rate		1.785%	1.785%

Hedging Instruments (Schedule O

Hedging Instruments (Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments) (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Derivatives, Fair Value [Line Items]
Total hedging instruments presented on the balance sheet	$ 101,904	$ 2,440
Hedging Liabilities, Gross amounts subject to master netting arrangements not offset on the balance sheet	2,108	1,323
Hedging Liabilities, Net amount	99,796	1,117
Cash Flow Hedges [Member]
Derivatives, Fair Value [Line Items]
Total hedging instruments presented on the balance sheet	2,979	2,440
Derivatives Designated As Hedging Instruments [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Total derivative instruments presented as cash flow hedges on the balance sheet	10,349	12,226
Hedging Assets, Gross amounts subject to master netting arrangements not offset on the balance sheet	2,108	1,323
Hedging Assets, Net amount	8,241	10,903
Foreign Currency Exchange Contracts [Member] | Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Total hedging instruments presented on the balance sheet	1,227	1,323
Foreign Currency Exchange Contracts [Member] | Other Long-Term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Total hedging instruments presented on the balance sheet	882
Foreign Currency Exchange Contracts [Member] | Derivatives Designated As Hedging Instruments [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Total derivative instruments presented as cash flow hedges on the balance sheet	10,062	12,226
Foreign Currency Exchange Contracts [Member] | Derivatives Designated As Hedging Instruments [Member] | Other Long-Term Assets Net [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Total derivative instruments presented as cash flow hedges on the balance sheet	287
Interest Rate Swaps [Member] | Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Total hedging instruments presented on the balance sheet	870	$ 1,117
Foreign Currency Borrowings Designated As Net Investment Hedge On The Balance Sheet [Member] | Long-term Debt [Member]
Derivatives, Fair Value [Line Items]
Total hedging instruments presented on the balance sheet	$ 98,925

Hedging Instruments (Gain (Loss

Hedging Instruments (Gain (Loss) Recognized In Other Comprehensive Income On Derivative Instruments (Effective Portion)) (Details) - Derivatives Designated As Hedging Instruments [Member] - Cash Flow Hedges [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in OCI on Derivative Instruments (Effective Portion)	$ (6,235)	$ (1,673)	$ (2,014)	$ (2,075)
Foreign Currency Exchange Contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in OCI on Derivative Instruments (Effective Portion)	(6,349)	(1,698)	(2,170)	(2,215)
Interest Rate Swaps [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in OCI on Derivative Instruments (Effective Portion)	$ 114	$ 25	$ 156	$ 140